SCHEMBL4979252

SCHEMBL4979252

Cn1cnc2c(=O)n(-c3ccc(Cl)cc3)c(CC(C)(C)CC(F)(F)F)nc21

nearest known ligand 0.35

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CNR1 P21554 3/20 0.35
DRD1 P21728 2/20 0.35
DRD5 P21918 2/20 0.35
LMNA P02545 1/20 0.34
TSHR P16473 1/20 0.34
XBP1 P17861 1/20 0.34
HTT P42858 1/20 0.34
NPSR1 Q6W5P4 1/20 0.34
MAT2A P31153 1/20 0.34
MAOA P21397 3/20 0.34
MAOB P27338 3/20 0.34
KCNN2 Q9H2S1 1/20 0.33
KCNN3 Q9UGI6 1/20 0.33
NPC1 O15118 1/20 0.33
POLB P06746 1/20 0.32
GRM1 Q13255 1/20 0.32
TBXA2R P21731 1/20 0.32
CDK1 P06493 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4522751 0.88 TSHR (0.38) DRD1DRD5LMNATSHRXBP1
SCHEMBL4514806 0.87 DRD1 (0.39) DRD1DRD5LMNATSHRXBP1
SCHEMBL4525318 0.84 CNR1 (0.38) CNR1DRD1DRD5LMNATSHR
SCHEMBL4517383 0.82 CNR1 (0.37) CNR1DRD1DRD5LMNATSHR
SCHEMBL4518633 0.81 CNR1 (0.36) CNR1DRD1DRD5LMNATSHR
SCHEMBL4506682 0.81 DRD1 (0.37) DRD1DRD5LMNATSHRXBP1
SCHEMBL4429967 0.80 DRD1 (0.43) CNR1DRD1DRD5LMNATSHR
SCHEMBL4981265 0.80 DRD1 (0.43) CNR1DRD1DRD5LMNATSHR
SCHEMBL4429964 0.80 DRD1 (0.43) CNR1DRD1DRD5LMNATSHR
SCHEMBL4427546 0.80 DRD1 (0.44) CNR1DRD1DRD5LMNATSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080090845-A1 Haloalkyl-substituted pyrimidinone derivatives NEUROGEN CORPORATION (US) 2008-04-17 US claimed
US-20080090845-A1 Haloalkyl-substituted pyrimidinone derivatives NEUROGEN CORPORATION (US) 2008-04-17 US disclosed
US-20080090845-A1 Haloalkyl-substituted pyrimidinone derivatives NEUROGEN CORPORATION (US) 2008-04-17 US disclosed
US-20080090845-A1 Haloalkyl-substituted pyrimidinone derivatives NEUROGEN CORPORATION (US) 2008-04-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080090845-A1 Haloalkyl-substituted pyrimidinone derivatives PIGS, GPR174, GPR17 CNR1 26/4885DRD1 1261/4885DRD5 1056/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.